Trial Profile
A Randomized, Open-label, Multi-part Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Entecavir (Primary) ; NVR 3778 (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Alios BioPharma
- 16 Oct 2017 Status changed from recruiting to discontinued.
- 18 Jul 2017 Planned End Date changed from 1 May 2017 to 31 May 2018.
- 18 Jul 2017 Planned primary completion date changed from 1 May 2017 to 31 May 2018.